跳至主要内容
临床试验/NCT03405688
NCT03405688已完成不适用

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

Hanane EL KENZ3 个研究点 分布在 1 个国家目标入组 173 人开始时间: 2018年2月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
173
试验地点
3
主要终点
Hemoglobin level -patient

研究概览

简要总结

Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • All patients with sickle cell disease within the CHU Brugmann and the Queen Fabiola Children's Hospital (HUDERF)

排除标准

  • 未提供

研究组 & 干预措施

Control - Transfusion prior to surgery

Other

Blood donor not bearer of the sickle cell disease allele (HbAA genotype)

干预措施: Blood sampling (Procedure)

Acute transfusion

Experimental

Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)

干预措施: Blood sampling (Procedure)

Control - Acute transfusion

Other

Blood donor not bearer of the sickle cell disease allele (HbAA genotype)

干预措施: Blood sampling (Procedure)

Chronic transfusion

Experimental

Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)

干预措施: Blood sampling (Procedure)

Control - Chronic transfusion

Other

Blood donor not bearer of the sickle cell disease allele (HbAA genotype)

干预措施: Blood sampling (Procedure)

Transfusion prior to surgery

Experimental

Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)

干预措施: Blood sampling (Procedure)

结局指标

主要结局

Hemoglobin level -patient

时间窗: 1 hour after blood transfusion

Hemoglobin level (g/dL)

% of 'S' type hemoglobin -transfused blood

时间窗: 1 hour before blood transfusion

% of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese)

% of 'S' type hemoglobin -patient

时间窗: 1 hour after blood transfusion

% of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese)

Hemoglobin level - transfused blood

时间窗: 1 hour before blood transfusion

Hemoglobin level (g/dL)

Transfusion yield

时间窗: 1 hour after blood transfusion

Computed by means of a formula taking the level of hemoglobin, the % of 'S' type hemoglobin and the body surface into account.

Medical complications

时间窗: 1 month

List of medical complications having occured after a surgery. Applicable only to the 'transfusion prior to surgery' groups.

Length of stay

时间窗: 1 month

Length of stay within the hospital. Applicable only to the 'acute transfusion' groups

Length of stay post transfusion

时间窗: 1 month

Length of stay within the hospital after a blood transfusion. Applicable only to the 'acute transfusion' groups

Number of blood transfusions

时间窗: 1 month

Number of blood transfusions. Applicable only to the 'acute transfusion' groups

Hospital re-admission

时间窗: 1 month

Hospital re-admission. Applicable only to the 'acute transfusion' groups

Mortality rate

时间窗: 1 month.

Mortality rate. Applicable only to the 'acute transfusion' groups

次要结局

未报告次要终点

研究者

发起方
Hanane EL KENZ
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Hanane EL KENZ

Head of Blood Bank

Brugmann University Hospital

研究点 (3)

Loading locations...

相似试验